NCT01904903View on ClinicalTrials.gov

Cardiac Safety Study in Patients With HER2 + Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2020

Conditions
HER2 Positive Breast CancerLeft Ventricular Function Systolic Dysfunction
Interventions
DRUG

Trastuzumab

HER2 therapy

DRUG

Pertuzumab

HER2 therapy

DRUG

Ado Trastuzumab Emtansine

HER2 therapy

Trial Locations (2)

20010

Washington Cancer Institute at MedStar Washington Hospital Center, Washington D.C.

20057

MedStar Georgetown University Hospital, Washington D.C.

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Medstar Health Research Institute

OTHER

NCT01904903 - Cardiac Safety Study in Patients With HER2 + Breast Cancer | Biotech Hunter | Biotech Hunter